GlassScriptPhysician profile
Kaitlyn Grace Carmo
NPI 1417608266
$5,550.13
in general payments reported to CMS, 2019-2025
22 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $730 · 2023: $788 · 2024: $3,004 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,488 · Travel and Lodging: $1,287 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,488.46 |
| Travel and Lodging | $1,286.58 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,705.85 | 2024 | Linq II |
| Boehringer Ingelheim Pharmaceuticals, INC. | $473.01 | 2022-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $467.25 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $425.82 | 2022-2025 | |
| Atricure, INC. | $421.56 | 2023-2024 | |
| Pfizer INC. | $412.11 | 2022-2025 | |
| Amgen INC. | $275.90 | 2022-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $220.43 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $190.36 | 2025 | Wegovy |
| Abbott Laboratories | $147.04 | 2025 | Cardiomems |
| Scpharmaceuticals INC. | $120.33 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $117.41 | 2022-2025 | Camzyos, Eliquis |
| Agepha Pharma Fz LLC | $99.60 | 2025 | Lodoco |
| Esperion Therapeutics, INC. | $91.10 | 2024-2025 | Nexletol |
| Kestra Medical Technology Services, INC. | $84.46 | 2024-2025 | Assure Wcd |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $74.80 | 2023 | Remede System |
| Merck Sharp & Dohme LLC | $62.96 | 2024-2025 | Verquvo |
| Inspire Medical Systems, INC. | $60.56 | 2024-2025 | Inspire |
| Kiniksa Pharmaceuticals International, Plc | $43.89 | 2024 | Arcalyst |
| Daiichi Sankyo INC. | $27.20 | 2025 | Injectafer |
| Glaxosmithkline, LLC. | $14.51 | 2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $13.98 | 2024 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlyn Carmo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.